Charles Schwab
JANX icon

Charles Schwab’s Janux Therapeutics JANX Stock Holding History

Charles Schwab’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.67M Buy
369,191
+14,863
+4% +$215K ﹤0.01% 2419
2026
Q1 		$4.93M Sell
354,328
-36,178
-9% -$496K ﹤0.01% 2412
2025
Q4 		$5.39M Buy
390,506
+35,962
+10% +$846K ﹤0.01% 2413
2025
Q3 		$8.67M Buy
354,544
+55,167
+18% +$1.34M ﹤0.01% 2178
2025
Q2 		$6.92M Buy
299,377
+25,734
+9% +$678K ﹤0.01% 2185
2025
Q1 		$7.39M Buy
273,643
+508
+0.2% +$19.1K ﹤0.01% 2102
2024
Q4 		$14.6M Buy
273,135
+38,944
+17% +$2.06M ﹤0.01% 1848
2024
Q3 		$10.6M Buy
234,191
+156,675
+202% +$6.82M ﹤0.01% 1996
2024
Q2 		$3.25M Buy
77,516
+28,258
+57% +$1.33M ﹤0.01% 2535
2024
Q1 		$1.85M Buy
49,258
+3,117
+7% +$67.9K ﹤0.01% 2616
2023
Q4 		$495K Sell
46,141
-2,609
-5% -$22.6K ﹤0.01% 3076
2023
Q3 		$491K Buy
48,750
+2,629
+6% +$30.3K ﹤0.01% 3043
2023
Q2 		$547K Buy
46,121
+729
+2% +$9.74K ﹤0.01% 3006
2023
Q1 		$549K Sell
45,392
-2,298
-5% -$38.2K ﹤0.01% 2922
2022
Q4 		$628K Buy
47,690
+1,127
+2% +$16.5K ﹤0.01% 2921
2022
Q3 		$631K Buy
46,563
+4,053
+10% +$54.2K ﹤0.01% 2935
2022
Q2 		$520K Sell
42,510
-1,890
-4% -$22.4K ﹤0.01% 3063
2022
Q1 		$637K Buy
44,400
+10,454
+31% +$171K ﹤0.01% 3026
2021
Q4 		$670K Buy
33,946
+1,370
+4% +$28.7K ﹤0.01% 3056
2021
Q3 		$705K Buy
+32,576
New +$937K ﹤0.01% 3021

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Charles Schwab's JANX Position: Q2 2026 in Review

Charles Schwab increased its Janux Therapeutics (JANX) stake by 4.2% in Q2 2026, buying an estimated $215K and bringing the position to 369,191 shares worth $5.67M. The position accounts for ﹤0.01% of the portfolio, ranked #2419.

Charles Schwab first reported a position in JANX in Q3 2021 and has held it in 20 quarters since. The position peaked at $14.6M in Q4 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Charles Schwab held 369,191 shares of Janux Therapeutics worth $5.67M as of Q2 2026.
  • Charles Schwab bought 14,863 Janux Therapeutics shares in Q2 2026, an estimated $215K.
  • Janux Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2419 holding.
  • Charles Schwab first reported a position in Janux Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Charles Schwab's Janux Therapeutics position peaked at $14.6M in Q4 2024.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.